Publications by authors named "C Skrabs"
Article Synopsis
- Antiphospholipid syndrome is an autoimmune disorder that causes blood clots and pregnancy issues due to persistent antiphospholipid antibodies.
- Treatment typically involves long-term anticoagulation therapy, which only manages symptoms and doesn't cure the condition.
- A case study shows that a woman treated with CAR T-Cell therapy for lymphoma achieved a lasting reduction in all types of antiphospholipid antibodies, indicating a potential new treatment avenue using immunotherapy.
Background: Chimeric antigen receptor T (CART) cell therapy targeting the B cell specific differentiation antigen CD19 has shown clinical efficacy in a subset of relapsed/refractory (r/r) diffuse large B cell lymphoma (DLBCL) patients. Despite this heterogeneous response, blood pre-infusion biomarkers predicting responsiveness to CART cell therapy are currently understudied.
Methods: Blood cell and serum markers, along with clinical data of DLBCL patients who were scheduled for CART cell therapy were evaluated to search for biomarkers predicting CART cell responsiveness.
Objective: We aimed to investigate whether (1) psychological and social indicators influence survival in patients diagnosed with cancer or haematologic malignancies when important biological aspects are controlled for, (2) psychological, social and biological indicators can be utilised to design one collated index for survival, usable in clinical practice to identify patients at risk of shorter survival and to improve personalised healthcare provision.
Methods: In this cross-sectional study, 2263 patients with cancer or haematologic malignancies participated. We analysed 15 biological, psychological and social indicators as risk factors for survival with a Cox proportional hazards model.
Article Synopsis
- * A study involving 170 DLBCL patients treated with either CAR T-cell therapy or conventional therapies found that certain mutations affected overall survival differently, depending on the treatment type.
- * In patients receiving CAR T-cell therapy, the presence of these mutations did not significantly impact survival rates, highlighting the need for further research in larger groups.